UBE2U

Across TCGA pan-cancer cohorts, UBE2U Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated UBE2U data layer compared with 14 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher UBE2U Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2U expression acts as an unfavorable survival marker.

SARC and LIHC are the cancer types where UBE2U Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.085	0.839	<.001	12	view →
LIHC	OS	Median	All	0.123	0.707	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

UBE2U–SARC (OS)

Open the SARC breakdown →